Congenital Heart Disease Linked to Maternal Autoimmunity against Cardiac Myosin

Charles R. Cole, Katherine E. Yutzey, Anoop K. Brar, Lisa S. Goessling, Sarah J. VanVickle-Chavez, Madeleine W. Cunningham and Pirooz Eghtesady

*J Immunol* published online 26 March 2014
http://www.jimmunol.org/content/early/2014/03/26/jimmunol.1301264

**Supplementary Material**  
http://www.jimmunol.org/content/suppl/2014/03/26/jimmunol.1301264.DCSupplemental

**Subscription**  
Information about subscribing to *The Journal of Immunology* is online at:  
http://jimmunol.org/subscription

**Permissions**  
Submit copyright permission requests at:  
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**  
Receive free email-alerts when new articles cite this article. Sign up at:  
http://jimmunol.org/alerts
Congenital Heart Disease Linked to Maternal Autoimmunity against Cardiac Myosin

Charles R. Cole,* Katherine E. Yutzey,* Anoop K. Brar,† Lisa S. Goessling,†
Sarah J. VanVickle-Chavez,† Madeleine W. Cunningham,*‡ and Pirooz Eghtesady*†

Structural congenital heart disease (CHD) has not previously been linked to autoimmunity. In our study, we developed an autoimmune model of structural CHD that resembles hypoplastic left heart syndrome (HLHS), a life-threatening CHD primarily affecting the left ventricle. Because cardiac myosin (CM) is a dominant autoantigen in autoimmune heart disease, we hypothesized that immunization with CM might lead to transplacental passage of maternal autoantibodies and a prenatal HLHS phenotype in exposed fetuses. Elevated anti-CM autoantibodies in maternal and fetal sera, as well as IgG reactivity in fetal myocardium, were correlated with structural CHD that included diminished left ventricular cavity dimensions in the affected progeny. Further, fetuses that developed a marked HLHS phenotype had elevated serum titers of anti-β-adrenergic receptor Abs, as well as increased protein kinase A activity, suggesting a potential mechanism for the observed pathological changes. Our maternal–fetal model presents a new concept linking autoimmunity against CM and cardiomyocyte proliferation with cardinal features of HLHS. To our knowledge, this report shows the first evidence in support of a novel immune-mediated mechanism for pathogenesis of structural CHD that may have implications in its future diagnosis and treatment. The Journal of Immunology, 2014, 192: 000–000.

Received for publication May 22, 2013. Accepted for publication February 18, 2014.

This work was supported in part by National Institutes of Health Grants R21-HL104391 (to P.E.), F32-HL103054 (to C.R.C.), R01-HL56267 (to M.W.C.), and R37-HL35280 (to M.W.C.) and funds from the Saving Tiny Hearts Society. M.W.C. is the recipient of a National Heart, Lung, and Blood Institute Method to Extend Research in Time Award.

Address correspondence and reprint requests to Dr. Pirooz Eghtesady, Pediatric Cardiothoracic Surgery, Washington University School of Medicine, Campus Box 8254, St. Louis, MO 63110. E-mail address: eghtesadyp@wudosis.wustl.edu

The online version of this article contains supplemental material.

Abbreviations used in this article: β-AR, β-adrenergic receptor; CHD, congenital heart disease; CM, cardiac myosin; HLHS, hypoplastic left heart syndrome; LV, left ventricle (ventricular); PKA, protein kinase A; RV, right ventricle (ventricular).

Copyright © 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.00
in high-salt buffer, ammonium sulfate was increased to 33%, and the KC1 concentration was increased to 0.5 M. After the actomyosin pellet and salts were dissolved, ATP was added to 10 mM and MgCl2 was added to 5 mM, and then the solution was centrifuged at 20,000 × g for 15 min to remove actin filaments. The supernatant was removed and stored at 4°C in the presence of the following inhibitors: 0.5 mM PMSF, 5 μg/ml N-tosyl-L-lysine chloromethyl ketone, and 1 μl leupeptin per milliliter. The presence of CM was verified and quantitated by ELISA and Western immunoblot using mAb specific for CM protein.

Immunization protocol
Specific pathogen-free female Lewis rats (LEW-RTI) (∼8 wk old) were purchased from Charles River Laboratories (Raleigh, NC) and were maintained in a pathogen-free environment at Cincinnati Children’s Hospital animal facility. Rats were acclimated for 7 d prior to entering the immunization protocol. All animals were treated according to institutional guidelines and Institutional Animal Care and Use Committee–approved protocols. Female rats were immunized with either rat cardiac CM (n = 8) or saline (controls; n = 5). A schematic of the immunization protocol is shown in Supplemental Fig. 1. The rats treated with CM were immunized on day 0 by s.c. injection of 1 mg rat CM extract emulsified in CFA at a 1:1 ratio (v/v) in a total volume of 400 μl. On days 14, 28, and 42 after the initial immunization, all the rats were boosted i.p. with 500 μg extract emulsified in a total volume of 200 μl. Serum titers of CM Abs were determined by ELISA assays every 7–14 d. Rats with no response (<1:100) exited the protocol, and rats with medium titers (1:1–6400) were given up to a total of three additional boosters. In the control group, CM extract was exchanged for saline in the presence of adjuvant.

Blood samples were centrifuged at 1300 g for 15 min in a fixed angle rotor. Serum was collected and stored at −20°C. Maternal and fetal blood was collected during harvest. Maternal animals were harvested following decapitation, and maternal animals after a vaginal smear. Vaginal smears were performed daily. Near-term (estimated mated day of gestation 20 ± 1 d) cesarean section was performed with the rats under anesthesia (1.5% isoflurane) to deliver the progeny. Fetal animals were harvested following decapitation, and maternal animals after exsanguinations. Maternal and fetal blood was collected during harvest. Blood samples were centrifuged at 1300 × g for 15 min in a fixed angle rotor. Serum was collected and stored at −20°C. Maternal and fetal hearts were immediately washed in PBS, fixed in 4% paraformaldehyde, paraffin embedded, sectioned at 7-μm intervals, and histologically analyzed.

Ab quantification by direct ELISA
The assays were conducted as described in previous publications (21, 22, 25). Immulon 4 (Dynatech) microtiter plates were coated at 4°C overnight with rat CM at 10 mg/ml in 0.1 mol/l carbonate–bicarbonate coating buffer (pH 9.6). Plates were washed with PBS containing 0.05% Tween 20 and blocked for 1 h at 37°C with 1% BSA (Fisher Scientific, Hanover Park, IL). Plates were washed once again with PBS/Tween 20. To determine the rat anti-CM ELISA Ab titer, rat sera were titrated at an initial dilution of 1:500 in 1% BSA in PBS buffer and thereafter diluted 2-fold, up to a final dilution of 1:12,800. A total of 50 μl diluted serum was loaded into microwell wells in duplicates and incubated overnight at 4°C. Plates were washed 5× with PBS/Tween 20, and 50 μl goat anti-rat IgG (Sigma-Aldrich, St Louis, MO) conjugated with alkaline phosphatase (1/500 dilution) was added and incubated at 37°C for 1 h. Plates were washed with PBS/Tween 20, and 50 μl substrate para-nitrophenyl phosphate (Sigma-Aldrich) or 0.1 M diethanolamine buffer (pH 9.8) was added to each well. OD was measured at 405 nm in an ELISA plate reader (ELx800, Bio-Tek Instruments, Winooski, VT). Titers were highest dilution with an OD value of 0.10 at ≤60 min. Anti-rat CM Ab titers in the ELISA were standardized and controlled using negative and positive control standard sera, obtained from previous experiments. β-adrenergic receptors (β-AR) 1 (β1-AR) and 2 (β2-AR) (PerkinElmer) were coated at 10 μg/ml onto microtiter plates for testing for rat IgG Abs against the anti-β1-AR and anti-β2-AR Abs in the serum. ELISA was performed according to the same procedure stated above. Activation of serum protein kinase A (PKA) by the β-AR was performed as previously described (21, 22).

Histology and morphometry studies
Sections from each fetal heart were stained with Movat’s pentachrome or Masson’s trichrome (both from American Mastertech Scientific). All morphometric measurements were obtained using ImageJ software. Comparable apical four-chambered sections from each fetal heart were photographed (Nikon DS R1) and coded to eliminate bias. Two blinded observers obtained measurements. At the left ventricular (LV) and right ventricular (RV) lateral and apical free walls, three measurements were taken in 100-μm intervals. Three area measurements of the LV and RV were also obtained using comparable apical four-chambered sections. Measurements were then averaged from each location for statistical analysis. Owing to some cardiac damage during harvest that altered heart chamber dimensions, two affected and two unaffected fetal hearts were excluded from LV/RV lumen area measurements. Maternal hearts were processed as previously described (20). A veterinary pathologist evaluated maternal heart sections for the presence of myocarditis and valvulitis.

Western blot analysis
Binding of maternal and fetal serum to lysesates (10 μg total protein) of adult rat heart, liver, lung, and spleen was determined by Western blot analysis, as previously described (22). Sera from CM-injected maternal rats and affected fetal offspring, along with sera from control maternal rats and fetal offspring, were analyzed at a dilution of 1:1000. Preincubation of the sera with porcine CM (20 μg; Sigma-Aldrich) prior to incubation of the blots was performed to determine specificity.

Immunohistochemistry studies
The anti-rat IgG staining was performed as previously described, with slight modifications, (21) and was γ-chain specific for rat IgG. Briefly, mounted tissues were baked at 60°C for 20 min and deparaffinized using a 3:1 ratio of Hemo-D (Fisher) to xylene. After rehydration in graded ethanol washes, tissues were washed twice with PBS, blocked with Protein Block (BioGenex, San Ramon, CA) for 30 min at room temperature, and washed twice with PBS, 1% type control goat IgG biotin or biotin-conjugated goat anti-rat IgG Abs (diluted 1:500; Jackson ImmunoResearch, West Grove, PA) were incubated on tissues overnight at 4°C in a humidity chamber, followed by three washes in PBS. Alkaline phosphatase–conjugated streptavidin was incubated with the tissues at 1 mg/ml for 30 min at room temperature. After three washes in PBS, Ab binding was detected with Fast Red substrate (BioGenex) against a counterstain of Mayer’s hematoxylin (BioGenex). Slides were mounted with crystal mount (Fisher), dried, and coverslipped using Permount (Sigma Chemical) The amount of IgG band is indicated by scoring the intensity of visual Fast Red staining in the heart tissue. Similar to the previously described process, sections were deparaffinized and rehydrated and then had antigenic sites unmasked using the citrate-based solution (#H-3300; Sigma-Aldrich) and high temperature–pressure protocol of Vector Laboratories. Sections were blocked for 1 h at room temperature with 8% normal goat serum (#G9023; Sigma-Aldrich), then incubated overnight at 40°C with primary Abs PHH3 (#060-570 [1:350]; Millipore), to identify mitotic cells, and MF20 (#MF2 1:200); Developmental Studies Hybridoma Bank), to identify myocytes. For immunofluorescent detection, sections were incubated with Alexa Fluor-conjugated secondary Abs (goat anti-rabbit IgG #A11011 and goat anti-mouse IgG #A11001 [1:100]; Invitrogen) for 1 h at room temperature, followed by a 30-min incubation with the nuclear stain TO-PRO-3 (#T3605 [1:1000]; Invitrogen). Samples were imaged using a Zeiss LSM 510 confocal microscope. The total number of nuclei, the number of nuclei in myocytes, the total number of phospho-positive nuclei, and the number of pH3-positive nuclei in myocytes were counted for each image, using ImageJ software. The total proliferative rate was calculated using total pH3-positive nuclei divided by total nuclei. To determine the mitotic index, counts from four areas of the LV, using comparable areas from each heart, were totaled and used to calculate the percentage of pH3-positive nuclei. TUNEL staining (cat. no. 11 684 809 910; Roche Applied Science) was performed according to the manufacturer’s instruction. Cardiomyocytes were identified using MF20 staining, and the cardiomyocyte-specific proliferative marker was calculated at the highest intensity of positive staining in each section.

Statistical analysis
All statistical analyses were completed using SAS version 9.2. Two variables were analyzed using two-sided, independent sample t tests, and three variables were analyzed with two-way ANOVA with Tukey–Kramer adjustment for multiple comparisons.

Results
Heart defects correlated with elevated anti-CM titers
Female Lewis rats immunized with CM developed peak anti-CM autoantibody titers ranging from 1:6000 to >1:12,800, prior to pregnancy (Fig. 1A). Most importantly, all maternal rats (n = 8 mothers with 47 fetuses) with elevated anti-CM Ab titers had at
were injected with adjuvant, and their offspring (Table I). Control animals, which ranged from 1:200 correlated with maternal peak CM titers of 105 (2) 29 (2) 14 (1) 29 (2) 0

Table I. Maternal immune response against CM and associated left-sided structural congenital cardiac abnormalities in the progeny

<table>
<thead>
<tr>
<th>Fetal Litter</th>
<th>Litter Size</th>
<th>Total Maternal Ab Burden</th>
<th>Progeny with Heart Defects, % (No. Affected)</th>
<th>LV Cavity Hypoplasia, % (No. Affected)</th>
<th>Loss of Normal Valve Structure, % (No. Affected)</th>
<th>Severely Increased LV Myocardial Wall Thickness, % (No. Affected)</th>
<th>Moderately Increased LV Myocardial Wall Thickness, % (No. Affected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CM4</td>
<td>11</td>
<td>3.2 × 10^5</td>
<td>36 (4)</td>
<td>27 (3)</td>
<td>36 (4)</td>
<td>9 (1)</td>
<td>18 (2)</td>
</tr>
<tr>
<td>CM5</td>
<td>12</td>
<td>4.0 × 10^5</td>
<td>8 (1)</td>
<td>8 (1)</td>
<td>8 (1)</td>
<td>8 (1)</td>
<td>0</td>
</tr>
<tr>
<td>CM7</td>
<td>8</td>
<td>2.6 × 10^5</td>
<td>25 (2)</td>
<td>25 (2)</td>
<td>25 (2)</td>
<td>25 (2)</td>
<td>0</td>
</tr>
<tr>
<td>CM8</td>
<td>9</td>
<td>7.3 × 10^5</td>
<td>67 (6)</td>
<td>55 (5)</td>
<td>44 (4)</td>
<td>55 (5)</td>
<td>11 (1)</td>
</tr>
<tr>
<td>CM10</td>
<td>7</td>
<td>2.3 × 10^5</td>
<td>29 (2)</td>
<td>29 (2)</td>
<td>14 (1)</td>
<td>29 (2)</td>
<td>0</td>
</tr>
<tr>
<td>C1</td>
<td>13</td>
<td>&lt;100</td>
<td>0 (0)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C2</td>
<td>3</td>
<td>&lt;100</td>
<td>0 (0)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>C3</td>
<td>3</td>
<td>&lt;100</td>
<td>0 (0)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

The total maternal Ab burden was calculated using area under the curve of the maternal Ab titer graph (Fig. 1). The values given are the mean ± SEM of each litter. Neither maternal nor fetal adjuvant-injected control animals (C1–3) had elevated anti-CM Ab titers.

C, adjuvant injected controls; CM, CM-immunized; D, day.
lateral free wall ($p < 0.001$) and LV apical free wall ($p < 0.05$), compared with the adjuvant control group (Fig. 4A). Statistical analysis of the affected fetal hearts with the HLHS phenotype ($n = 15$) versus the unaffected fetal hearts ($n = 32$) and adjuvant controls (Fig. 4B) demonstrated no difference in RV myocardial thickness between the three groups. Further, the HLHS-like phenotype in fetal hearts had increased LV lateral free wall thickness, compared with the unaffected fetal hearts ($p < 0.0001$) and adjuvant controls ($p < 0.0001$). Affected fetal hearts with the HLHS-like phenotype also demonstrated increased LV apical free wall thickness, compared with the unaffected fetal hearts ($p = 0.0009$) and adjuvant controls ($p = 0.0001$). No significant difference was observed in the LV wall thickness of the unaffected compared with adjuvant control fetal hearts. These findings indicate that the maternal immune response against CM was associated with increased LV, but not RV, myocardial wall thickness.

The significant impact of HLHS results from altered development of the LV and left-sided valve structures, characterized by a reduced, or hypoplastic, LV cavity, rendering the heart unable to support the systemic circulation (29, 30). To determine ventricular chamber size in our model, the LV lumen area and RV lumen area of each specimen were measured, and an LV/RV lumen area ratio was used to determine relative LV chamber size. The RV served as an internal control for this comparison. The affected HLHS-like phenotype had a significantly decreased LV/RV lumen area ratio when compared with the unaffected normal fetal hearts ($p = 0.002$) and adjuvant controls ($p = 0.007$) (Fig. 4C). No significant difference in the LV/RV lumen area ratio was noted between unaffected and adjuvant control fetal hearts. These findings indicate that the affected fetal hearts had a hypoplastic LV cavity reminiscent of HLHS in human infants.

**Increased Ab binding in affected hearts**

Because maternally acquired IgG is essential in newborn immunity, and maternally transferred Abs can mediate tissue injury (31, 32), we examined IgG binding to the fetal hearts in our study. The myocardium of affected fetal hearts with the HLHS phenotype had increased IgG deposition, compared with unaffected fetal hearts ($p = 0.03$) and adjuvant controls ($p = 0.002$) (Fig. 5). Moreover, IgG deposition in the hearts of offspring of CM-immunized mothers correlated with the observed cardiac malformations. The IgG deposition was principally found in the fetal myocardium, with minimal staining on valve structures or atrioventricular cushions. There was no IgG deposition in maternal heart sections from CM-treated or control groups.

**Cardiomyocyte proliferation increased in the HLHS phenotype**

Although the causes of certain subtypes of HLHS may originate through primary valve defects (7, 28, 33), there is evidence that HLHS may result as a consequence of abnormal myocyte proliferation during development (34, 35). Further, to determine whether increased cardiomyocyte proliferation contributed to the thickening of the LV myocardium in our model, both compact and trabeculated myocardium were examined, as the pathological specimens had increased thickness of both. Affected fetal hearts with the HLHS phenotype had an increased total LV proliferative rate, compared with the unaffected fetal hearts ($p = 0.05$) and adjuvant controls ($p = 0.003$) (Fig. 6A, 6B). The affected fetal hearts with the HLHS phenotype had an increased cardiomyocyte-specific proliferative rate, compared with the unaffected fetal hearts ($p = 0.05$) and adjuvant controls ($p = 0.002$) (Fig. 6C). In contrast, no significant differences were found between groups in the proliferative rate of nonmyocyte nuclei or in apoptosis of the myocardium or valve structures (data not shown). Further, maternal hearts from CM-treated groups did not display any abnormal histopathological features or changes in cardiomyocyte proliferation.

**Increased anti–β-AR titers in affected fetuses**

Our previous work has shown that anti-CM Abs cross-react with the β-AR on the cardiomyocyte surface and induce cAMP-dependent PKA activity in heart cells (21). Because the β-AR also plays a regulatory role in cardiomyocyte proliferation in early life (36), we measured anti–β-AR titers in affected fetuses that had elevated anti-CM titers. We found increased anti–β1-AR ($p = 0.007$)
and anti-β2-AR (p < 0.0001) (Fig. 7B) Ab titers in fetal sera from the CM treatment group, compared with adjuvant control sera. Because β-ARs on the heart cell surface stimulate cAMP-dependent PKA activity, we next incubated fetal sera with cultured rat heart cells (H9c2 primary cells) to determine if sera from CM-treated animals could modulate PKA activity. We found a significant increase in PKA activity above basal levels only in fetal sera from the CM treatment group that developed heart disease (affected group) compared with sera from unaffected and control groups (p = 0.00023) or controls (p = 0.00005) (Fig. 8). No significant difference was noted in PKA activity in sera from unaffected fetuses from the CM group or controls (p = 0.1849).

**Discussion**

This study presents data supporting a novel concept that defines an HLHS-like phenotype caused by a maternal autoimmune response against CM. Observations in our fetal rat model of elevated autoantibodies against CM, including heart-specific binding of CM-immunized maternal and affected fetal serum, IgG deposition in fetal rat hearts, and the appearance of an HLHS-like phenotype,
support the hypothesis of an immune-mediated pathogenic mechanism in the development of congenital HLHS-like lesions in the fetal rat heart.

Of human cases of HLHS, ≤70% show a reduced LV cavity surrounded by a thickened LV myocardium (4, 28). Affected fetal rat hearts from CM-immunized mothers displayed an HLHS phenotype similar to that of human infants, including the characteristic hypoplastic, or decreased, LV cavity dimensions, as well as reduced LV cavity size compared with the unaffected group (n = 15). Adjuvant control (n = 19 fetuses) (**p = 0.002) groups. Both affected and unaffected groups were immunized with CM. There is no difference between the unaffected group and the adjuvant control group in either total proliferation or cardiomyocyte-specific proliferation. (A and B) Original magnification ×400; scale bar, 50 μm. Three variables (C) were analyzed using two-way ANOVA with Tukey–Kramer adjustment for multiple comparisons. The data shown are the mean ± SEM.

was increased in the hearts of affected animals, which could contribute to the reduction of LV cavity size, as in HLHS. The severely malformed rat hearts also displayed a “spongy” LV myocardium, which has also been described in histopathology reports of HLHS (38).

The development of the congenital HLHS-like phenotype in our model in association with elevated titers against CM occurred in ~32% of fetal rats. This rate is comparable to that in other autoimmune animal models, including experimental models of neonatal lupus, in which congenital heart block phenotype was observed in 20–30% of immunized pups (39). Although it is not clear why the disease process is primarily localized to left-sided heart structures, it is well known that in fetal circulation oxygen- and Ab-rich blood returning from the placenta will preferentially pass through the foramen ovale into the left side of the heart. Thus, fetal left-sided heart structures that are exposed to higher maternal Ab concentrations could be more susceptible to damage than right-sided structures. Further, maternal hearts in animals immunized against CM did not demonstrate any structural or inflammatory cardiac defects of the myocardium or valves, when compared with adjuvant injected controls. Thus, our observations

FIGURE 5. Increased IgG deposition in the myocardium of affected hearts. Both affected and unaffected hearts were observed in the CM-immunized group (32% of fetal rats developed an HLHS-like phenotype). Anti-rat IgG, alkaline phosphatase conjugated, was used to detect IgG, as indicated by Fast Red substrate against a counterstain of Mayer’s hematoxylin. (A and C) Adjuvant control hearts demonstrated minimal anti-rat IgG staining. (B and D) Affected hearts demonstrated extensive anti-rat IgG binding, indicated by increased Fast Red substrate staining. Left-sided mitral valve (MV) identified by arrows on the affected heart. There is more IgG deposited within the myocardium of the affected hearts compared with valve structures. PBS-treated control sections did not stain red and were blue and negative for IgG (not shown). (E) Scored results for amount of anti-rat IgG deposition. The affected group (n = 15) had increased IgG deposition, compared with the unaffected group (n = 32 fetuses) (*p = 0.03) and adjuvant control (n = 19 fetuses) (**p = 0.002) groups. (A and B) Original ×20; scale bar, 600 μm. (C and D) Original magnification ×100; scale bar, 125 μm. Three variables (E) were analyzed using two-way ANOVA with Tukey–Kramer adjustment for multiple comparisons. Averages of data shown in bars are mean ± SEM.

FIGURE 6. Increased total proliferation and cardiomyocyte-specific proliferation of the LV myocardium in affected hearts with the HLHS phenotype. (A and B) Adjuvant control and affected hearts stained with pH3, MF-20, and TO-PRO-3. There were more pH3-positive nuclei in the affected heart compared with adjuvant control. Arrows indicate pH3-positive nuclei. (C) Histogram demonstrating that the percentage of pH3-positive total cells was greater in the affected group (n = 15) compared with the unaffected group (n = 32) (*p = 0.05) and adjuvant control (n = 19 fetuses) (**p = 0.003) groups. Myocytes were identified by MF-20 stain and manually counted. Myocyte-specific percentage of pH3-positive cells was greater in the affected group than in the unaffected (*p = 0.05) and adjuvant control (**p = 0.002) groups. Both affected and unaffected groups were immunized with CM. There is no difference between the unaffected group and the adjuvant control group in either total proliferation or cardiomyocyte-specific proliferation. (A and B) Original magnification ×400; scale bar, 50 μm. Three variables (C) were analyzed using two-way ANOVA with Tukey–Kramer adjustment for multiple comparisons. The data shown are the mean ± SEM.
suggest that the developing fetal heart is more or uniquely susceptible to immune-mediated injury than is the mature adult heart, and that immune responses against CM led to malformations of the LV.

The amount of IgG deposition in the myocardium of adult rodents immunized with CM has been shown to correlate with autoimmune manifestations (17, 21). We found that the maternal immune response against CM was associated with IgG deposition coincident with left-sided congenital heart malformations in their progeny. The relative lack of Ab staining in the valves suggested that in our model valvular abnormalities occurred secondary to the initial myocardial insult. Elevated anti-CM autoantibody titers in both maternal and fetal serum of the CM-immunized group indicated positive transplacental transfer of maternal anti-CM autoantibodies. Transplacental Ab-mediated injury to the fetal heart is the proposed mechanism for a variety of diseases of the fetus and newborn, including erythroblastosis fetalis (or hemolytic disease of the newborn), hypothyroidism, lupus erythematosus, pemphigus vulgaris, and thyrotoxicosis (40). There is also precedence for such a mechanism leading to fetal heart disease, in congenital heart block. Cardiac injury in congenital heart block is presumed to arise from the active transplacental transport of maternal IgG Abs into the fetal circulation. In this condition, injury to conduction tissue of the fetal heart by autoantibodies leads to destruction of normal pacing mechanisms (14–16).

Intrauterine and perinatal exposure of the fetus to maternal IgG during pregnancy takes place when the IgG is transported from mother to fetus across the placenta, beginning at ∼12 wk of gestation in humans (14, 32). Early findings of HLHS, as diagnosed via prenatal echocardiography, are appreciated between 14 and 24 wk of gestation in nearly all cases (41, 42). This gestational period correlates with the chronology of transplacental transfer of maternal IgG when maternally transferred Abs can mediate tissue injury (14). Recent work has demonstrated that myocytes in HLHS are well differentiated (37), suggesting that HLHS results from an in utero insult to the fetus after the completion of primary cardiac morphogenesis (i.e., after the first 8 wk of human pregnancy) and corresponding to about gestation day 15.5 in the rat (34, 37, 43). IgG Ab distribution in our model suggests that the heart defects in affected animals were primarily myocardial in origin and that the valve abnormalities may be secondary in nature.

We examined a possible mechanism by which the observed anti-CM IgG response in the CM group could lead to the fetal heart disease in our model. Passive transfer of cross-reactive anti-CM/anti-β-AR IgG autoantibodies into adult rats can cause myocardial injury (21). Further, immune absorption of circulating autoantibodies improves cardiac function of patients with cardiomyopathy (44, 45). In animal models, Ab-induced cardiomyopathy induced by stimulation of the β1-AR agonist can be prevented by pharmacological neutralization of functionally active anti–β1-AR Abs or by the elimination of Abs by anti–β1-AR–selective immune absorption (46). Moreover, blocking the β-AR inhibits cardiomyocyte proliferation (36), suggesting a key role for the β-AR in the heart. In addition, studies in rats and humans have shown that removal of IgG or of specific anti-CM and anti-β-AR Abs from the sera depletes the PKA activation properties of the sera (21, 22).

Studies in our rat model showed that fetal sera contained elevated IgG autoantibody titers against CM as well as the β-AR, and furthermore, only sera from affected fetuses stimulated PKA activity in rat heart cells in culture. These data strengthen our hypothesis that functional signaling autoantibodies reactive against both the CM and the β-AR are associated with the observed HLHS-like phenotype in the Lewis rat. Further, the known cross-reactivity between CM and the β-AR may mediate the increased cardiomyocyte proliferation contributing to the thickening of the LV myocardium and, subsequently, to a reduction in LV cavity size. Other antigenic targets are also plausible as etiological factors in abnormal fetal cardiomyocyte development resulting in an HLHS-like phenotype. Pathogenesis of certain kinds of CHD such as HLHS may be influenced, either wholly or in part, by alterations
in fetal cardiomyocyte proliferation or differentiation caused by autoantibodies directed to CM or related Ags.

In conclusion, our evidence suggests a potential novel autoimmune mechanism that may contribute in part to the pathogenesis of CHD such as HLHS. However, the immune response genes and factors that can have an impact on such a response—in particular, as seen in other autoimmune and cardiac diseases (47), including autoimmune myocarditis (17), remain to be elucidated. The presence of abundant IgG deposition primarily in the myocardium of affected fetuses, in addition to the absence of cellular inflammatory changes in the CM-immunized mothers and their offspring, may suggest an Ab-mediated alteration in susceptible individuals. The binding of IgG to the β-AR and activation of signaling by increasing PKA activity could be a potential plausible mechanism that stimulates myocyte proliferation, leading to the downstream pathological changes in morphology and histology seen in affected fetuses. The potential role of alterations in regulatory mechanisms of cardiomyocyte proliferation in the fetal myocardium in response to autoantibodies directed to CM, the β-AR, or other potential antigenic targets, deserves further scrutiny.

Acknowledgments

We thank Mitali Basu and Christopher Lam (Cincinnati Children’s Hospital Medical Center) for technical assistance with the immunization experiment; R. Scott Baker and Danielle Herbert (Cincinnati Children’s Hospital Medical Center) for tissue sectioning and morphological measurements; Adita Mascaro-Blanco, Kathy Alvarez, and Stanley Kosanue (University of Oklahoma Health Sciences Center) for excellent technical support for the immunoaassays, phosphohistone, and immunohistochemistry; and Dennis Hansemann (University of Cincinnati, Cincinnati, OH) for statistical support.

Disclosures

M.W.C. is Chief Scientific Officer for Moleculera Labs. The other authors have no financial conflicts of interest.

References


poplastic left heart syndrome myocytes are differentiated but possess a unique phenotype. Cardiovase. Pathol. 12: 23–31.


